Tikva is a late-stage pre-clinical stage biotech company founded by seasoned cell and gene therapy key opinion leaders. We are headquartered in Singapore, integrating with local academic environment with close collaboration with Baylor College of Medicine.
We endeavor to develop highly differentiated “off-the-shelf” cell therapy for solid tumors with plans to set up clinical trials in the USA and Singapore.
SINGAPORE and UNITED STATES — 22 JULY 2026 — Tikva Allocell today announced the successful closing of an $8 million Series
CAR-T cell therapy has revolutionized cancer treatment, but its efficacy against solid tumors remains limited due to challenges like poor CAR-T cell in-vivo survival. Tikva’s engineered SB9 EBVST platform will not only address a major resistance mechanism axis but also opens doors to more effective CAR T cell therapies for solid tumors.